In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...
Boston Scientific Corporation (NYSE:BSX) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 30, ...
Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.
CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...
In late March 2026, Boston Scientific reported three advances: positive CHAMPION-AF and HI-PEITHO trial results for its ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond ...
Investor's Business Daily on MSN
Boston Scientific just took a 9% header. Why analysts are still bullish
Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.
Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results